In The News
Antisense Oligos Tango with Tau Transcripts to Reverse Tauopathy – ALZForum
In an article about Dr. Miller’s newest Science Translational Medicine publication, ALZFORUM writes, “In collaboration with the pharmaceutical company Ionis in Carlsbad, California, Timothy Miller and his colleagues at Washington University in St. Louis designed a potent ASO that shuts down human tau gene expression in transgenic mouse models.”
New DNA-Like Drugs Show Promise in Treating Alzheimer’s – Scientific American
An article by Scientific American describes Dr. Miller’s Science Translational Medicine publication. “The small molecules cleared and prevented tau buildup in mice and monkeys.”
Molecule Throws Roadblock in Alzheimer’s Path – New Atlas
An article by New Atlas describing Dr. Miller’s STM work states, “When it comes to the drama of Alzheimer’s disease, the compound in the starring role as the villain is tau. It’s a protein that normally helps our neurons function properly, but one that can clump together into plaques that damage brain cells. Now researchers have figured out a way to lower tau levels by throwing a molecular bomb in the works that lead to its creation.”
Scientists Stop and Reverse Alzheimer’s-Related Brain Damage in Mice – Medical News Today
A news release by MNT examines Dr. Miller’s 2017 STM publication. “The team studied the effects of the synthetic molecules on crab-eating macaques. They administered two doses of antisense oligonucleotides or two doses of a placebo, 1 week apart, directly into the cerebrospinal fluid – as one would when treating humans. The trial revealed that, in monkeys too, the oligonucleotide reduces both tau RNA and tau protein in the brain. Tau protein levels were also reflected in the cerebrospinal fluid.”
Scientists Reverse Alzheimer’s-Like Symptoms in Mice – Engadget
Engadget states, “Scientists have discovered a way of counteracting proteins that cause Alzheimer’s-like symptoms including memory loss. Researchers at Washington University in St. Louis, Missouri focus on tau protein tangles.” in an article about Dr. Miller’s 2017 STM publication.
Recently Published Preclinical Data Show Reduction of Tau Improves Tauopathy Phenotypes in Mice – Ionis Pharmaceuticals
The news release describes the joint work on Dr. Miller and Ionis colleagues: “Ionis scientists, in collaboration with researchers at Washington University, led by Dr. Timothy Miller and Sarah DeVos, developed antisense oligonucleotides (ASOs) targeting human tau mRNA with the goal of reducing tau expression in the brain. The tau-targeting ASOs were tested in a series of in vivo preclinical studies to characterize the potential therapeutic benefit of reducing tau mRNA and tau protein in the treatment of tauopathies.”
Drug Compound Halts Alzheimer’s-Related Damage in Mice – Washington University Record
In an article by Tamara Bhandari about Dr. Miller’s newest Science Translational Medicine publication, Bhandari writes,”Researchers at Washington University School of Medicine in St. Louis have found a drug that can lower tau levels and prevent some neurological damage.”
This article has also appeared on: EurekAlert! of the American Association for the Advancement of Science, Science Daily, Sci Fi Generation news, and CelebStarz News.
Fighting Buildup of Tau Protein in Alzheimer’s by Targeting RNA – Chemical & Engineering News
A “News of The Week” article by Ryan Cross of C&EN explores Dr. Miller’s STM publication in which antisense oligonucleotide therapy reduced tau in mice. “Until now, strategies against tau have mainly involved the use of antibodies and small-molecule drugs. But Timothy M. Miller and colleagues at Washington University in St. Louis are taking a different approach. “We are turning down the production of the tau gene,” Miller says.”
New Drug Takes on Alzheimer’s by Sweeping for Protein Clumps – Voice of America News
In an article about Dr. Miller’s 2017 Science Translational Medicine publication, VoA writes,”Scientists have developed a drug capable of sweeping away abnormal protein clumps in the brain which are a hallmark of Alzheimer’s disease.”
This article also appeared in the Belgium Sun.
Synthetic Molecule Stops Tau-Related Damage in Animal Study – Bioscience Technology
An article by Bevin Fletcher of Bioscience Technology describes Dr. Miller’s new STM publication. “A new study in mice and monkeys has found that a drug compound, known as an antisense oligonucleotide, can lower levels of tau proteins and potentially treat neurodegenerative diseases such as Alzheimer’s.”
New Alzheimer’s drug compound ‘worth investigating’ – Manila Bulletin
An article by Agence France-Presse of the Manila Bulletin describes Dr. Miller’s Science Translational Medicine publication in which a new approach to slowing the ravages of Alzheimer’s disease shows promise in early studies on mice and monkeys. The approach is “worth investigating” in humans, according to the article.
Gene-Blocking Therapy Reverses Alzheimer’s-Like Symptoms in Mice – New Scientist
Andy Coghlan of New Scientist explores Dr. Miller’s STM work in a news article. “When Miller’s team gave the antisense treatment to cynomolgus monkeys, they saw around a 20 per cent reduction in the amount of tau detected in spinal fluid samples, with no apparent side effects – early evidence that the therapy may hold promise for treating humans.”
NIH Study Could Lead to Reversing Dementia – Montgomery County Sentinel
An article by the Montgomery County Sentinel describes Dr. Miller’s tau work. “Miller emphasized that his experiment does not prove dementia can be reversed but expressed optimism that his findings could be translated to humans.”
Scientists Discover Drug that ‘Sweeps’ Away Protein that Triggers Alzheimer’s – The Sun
The UK-based journal has written an article about Dr. Miller’s STM manuscript. “Dr David Reynolds from Alzheimer’s Research UK said: “This is a potentially powerful approach to targeting tau build-up in the brain.””
New Drug Prevents Alzheimer’s-Related Damage – I4U News
A news release by I4U News examines Dr. Miller’s Science Translational Medicine publication, stating “Reduction in tau protein prevents Alzheimer’s in mice, opens doors for new treatment method in humans.”
Tipping the Balance Toward Four-Repeat Tau Exacerbates Toxicity in Mice – ALZForum
An article by ALZForum describes Dr. Miller’s 2016 Neuron report in which Miller lab members tested an antisense oligonucleotide strategy for switching between 3R- and 4R-tau expression in mice, allowing them to evaluate the two isoforms in the same genetic background. “Taken together, the results suggest that 4R tau is indeed toxic in the brain. “The data all seemed to line up together, suggesting that 4R tau was inducing pathological changes in the mice,” said co-first author Kathleen Schoch of Washington University. “While observations tell us that 4R tau is not the only actor in tauopathies, this paper elegantly shows that it can be a major one,” said Gil Rabinovici of the University of California, San Francisco.”
ALS Ice Bucket Challenge helps fund Washington University’s research
Dr. Timothy Miller is featured in this news release describing how the money raised in the ALS Ice Bucket Challenge has helped discover new genetic causes of this disease.
NEALS Webinar: “C9: From ID (Identification) to Therapy”
Dr. Timothy Miller, Washington University, and Dr. Merit Cudkowicz, Massachusetts General Hospital, provide an update on the C9orf72 Natural History Study and discuss therapies in development for C9 patients. Steve Kolb, patient advocate, describes the motivation behind the project and explains how you can get involved.
Antisense ALS Trial: Antisense Therapy and the Creation of the SOD1 Protein.
Dr. Miller is featured in this MDA video about antisense oligonucleotides and their use in treating ALS.
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
This JOVE video details a pump surgery method and features Sarah L. DeVos, a Ph.D. graduate student in the Miller Laboratory at Washington University School of Medicine in St. Louis.
2011 MDA Telethon ALS Research Update
MDA presents an update regarding research on ALS, featuring Dr. Timothy M. Miller from Washington University in St. Louis. MDA is supporting a clinical trial of antisense therapy seeking to counteract the affects of a toxic version of the protein SOD1 in patients with an inherited form of ALS.
2010 MDA Telethon ALS Research Update
MDA presents an update regarding research on ALS, featuring Dr. Timothy M. Miller from Washington University in St. Louis.